首页> 外文期刊>Biochemistry >Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens
【24h】

Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens

机译:复制 - 富集的流感病毒和呼吸道合胞病毒荧光素酶报告者报告菌株用于共感染鉴定组合屏幕中的抗病毒化合物

获取原文
获取原文并翻译 | 示例
           

摘要

Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted coinfection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dos- response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.
机译:肌瘤病毒如流感病毒(IAV)和呼吸道合胞病毒(RSV)是主要的人类病原体,授权新的治疗剂的发展。建立高通量筛选方案,用于同时鉴定病原体和宿主靶向的候选物,我们试图用IAV和RSV繁殖细胞。然而,病毒复制动力学是不相容的,RSV信号窗口低,并且在初始屏幕中使用的IAV驱动的Minireplicon报告器测定缩小了宿主细胞范围并将测定限制为单循环感染。为了克服这些限制,我们开发了一种携带萤火虫荧光素酶的RSV菌株,融合到创新的通用小分子辅助截止域,其提高了测定信号窗口,以及同步IAV和RSV报告表达动力学并抑制了识别的过度活性融合蛋白RSV进入抑制剂对最近报告的RSV泛抗机制敏感。结合复制竞争力的重组IAV菌株储存纳米琥珀素酶,测定在人类呼吸道线上进行良好并支持多单身感染。通过筛选一套全全套的全国健康临床收集(NCC)验证,颁发议定书。这些测试屏幕表现出有利的测定参数和再现性。在概念验证活动中施用生物活性化合物的Lopac文库检测到许可的抗咪唑病毒治疗,利巴韦林和神经氨酰胺酶抑制剂扎沙纳米韦,并确定了两个意外的RSV特异性麦芽糖,芬雷雷雷雷脲和阿片受体拮抗剂BNTX-7。使用表达Renilla Luciferase的标准RecsV报道菌株在直接和正交的DOS-响应芯片中评估命中次数。

著录项

  • 来源
    《Biochemistry》 |2015年第36期|共16页
  • 作者单位

    Georgia State Univ Inst Biomed Sci Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Atlanta GA 30303 USA;

    Georgia State Univ Inst Biomed Sci Atlanta GA 30303 USA;

    Stanford Univ Dept Biol Stanford CA 94305 USA;

    Stanford Univ Dept Bioengn Stanford CA 94305 USA;

    Georgia State Univ Inst Biomed Sci Atlanta GA 30303 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号